man-hands-working-technology.jpg
Bob+Each-3.jpg
5081cw5tuz0-peter-kasprzyk.jpg
picjumbo.com_HNCK8984.jpg
adrian-161202.jpg
d1pa78snrh0-drew-coffman.jpg
matthew-maillet-87851.jpg
man-hands-working-technology.jpg

Helpline Resource Center


Education is integral to empowerment and finding the right course of action. This page contains our resources to help you learn about prostate cancer and how it affects you personally. Call our Helpline and experienced prostate cancer patients and advocates are available to answer your questions. Watch our educational videos to get a basic understanding about your medical records and what they mean, as this will help you understand the type of prostate cancer you have. We also have a list of support groups and useful books to provide clarity and guidance.

Scroll down to get started with your research.

SCROLL DOWN

Helpline Resource Center


Education is integral to empowerment and finding the right course of action. This page contains our resources to help you learn about prostate cancer and how it affects you personally. Call our Helpline and experienced prostate cancer patients and advocates are available to answer your questions. Watch our educational videos to get a basic understanding about your medical records and what they mean, as this will help you understand the type of prostate cancer you have. We also have a list of support groups and useful books to provide clarity and guidance.

Scroll down to get started with your research.

Bob+Each-3.jpg

Our Facilitators


Our Facilitators


Call the Helpline at (800) 641-7274 or email: help@pcri.org

PCRI facilitators are patients or relatives of patients who have been intensely trained about prostate cancer by Dr. Mark Scholz and other PCRI Medical Advisors. They understand your situation and are able to help. They have access to a Board of Medical Advisors to obtain information pertinent to an individual situation. The Helpline staff reviews medical articles from The Journal of Urology, Urology, the Journal of Clinical Oncology, The Oncologist, and Cancer to stay current with the latest developments in prostate cancer research and treatments. They can provide you with medical information and understand your situation. We recommend that you watch the brief educational videos below and collect your medical records. To assist the staff in answering questions, we suggest that callers be prepared to provide some background information such as: Patient’s Date of Diagnosis, PSA at Time of Diagnosis, Gleason Score at Diagnosis, Prior and Current Treatments, Current PSA, and Patient’s Location (U.S. State or Country). When sending your initial inquiry by email, please do not send attachments. Fill out a form and a facilitator will contact you promptly. Alternatively, they can be reached directly at 1 (800) 641-7274 or via email at help@pcri.org. 

 

JONATHAN LEVY 

was diagnosed in 2009 with intermediate risk prostate cancer, at age 63.  He underwent two years of androgen deprivation therapy (hormonal therapy), and radiation treatment.  After a few years off treatment, he developed metastatic recurrence in 2014, but continues to do very well with his current regimen.  He was surprised to find he had much fewer side effects when restarting androgen deprivation in 2014, than he did in 2009.  From the beginning, Jonathan has taken a proactive position regarding his own cancer treatment, researching and evaluating his options in light of the best currently available tests and procedures.  Jonathan is a retired Film Editor, and works from his home in Southern California. 

 

ROBERT (BOB) EACH

is a prostate cancer veteran who has been with PCRI from its inception, a close friend to the PCRI’s original Helpline facilitator, Harry Pinchot.  Over the years, Bob has also worked with many other organizations such as the Prostate Cancer Foundation, the Westlake Village Prostate Cancer Support Group, the Thousand Oaks Prostate Cancer Support Group, and the California Coalition for Prostate Cancer.  He has also served as the President of Los Angeles Prostate Cancer Support Group. In 1995, he was diagnosed with advanced metastatic prostate cancer at age 51, with a Gleason score of 9 and a PSA of over 100.  He consulted with the PCRI’s Co-Founder Dr. Stephen Strum, who put him on a combination of Lupron, Casodex, and Proscar.  He also started a clinical trial of an over-the-counter herbal substance called PC-SPES. When Bob was first diagnosed, he was given 6 months to 3 years to live. Now, 20 years later, at 71, he continues in excellent health. In his leisure time, he enjoys flying his airplanes and spending time with his lovely family. 

SILVIA COOPER

is the daughter of a prostate cancer patient.  She has been advocating for her father and managing his care since his initial prostate cancer diagnosis in 2000. Through her work on Helpline,  Silvia has been helping others on their prostate cancer journey since 2011. Her background in administration enabled her to also help PCRI with administrative needs. Due to her mother's death from cancer and her experience with her father's prostate cancer,  she is passionate about helping others through this difficult time in their lives.

 

CONTACT HELPLINE

We would love to help! Please fill out this form and our Helpline staff will get in touch with you shortly.

5081cw5tuz0-peter-kasprzyk.jpg

Prostate Imaging


THE NEW HORIZON IN PROSTATE CANCER TREATMENT

Prostate Imaging


THE NEW HORIZON IN PROSTATE CANCER TREATMENT

 

Transcript:

“So your PSA number came back high. What now?” 

Let’s say, like many men,  you’ve been getting your PSA checked every year as part of your routine checkup. In the past it has always hovered around 2 or maybe as high as 3.0, and suddenly it’s up to 5! Or maybe this is your first PSA test. Everyone knows that 4.0 is the magic number, anything above that means something is not right with your prostate. Right? Actually, it’s a lot more complicated than that, but for this video we’ll take that as a given. OK, so the number is high, what do you do? Well, if you’re like many men your first instinct might be something like this…

“Aaaah,  I’ve got prostate cancer! Cut the *****ing thing out”!

Unfortunately there are a bunch of people in the medical community that will support and even encourage that instinct. It’s the wrong instinct.

Wait.

Slow down.

Take a deep breath.

Now just to be clear, this video is not advocating any sort of wonder-cure and we’re not downplaying how serious prostate cancer can be. Everything we’ll talk about here is backed up by good science, the latest technology, and highly trained medical professionals.

Let’s stop and talk for a second about the prostate. No offense to our creator, or to evolution or whatever you believe about human origins, but you couldn’t find a worse place to situate an organ, especially one that can be prone to problems. It’s…”down there”. And it’s in the middle of everything “down there”. Your urethra, that tube that carries urine out from the bladder, runs right through it… as do a couple of nerve bundles that control your ability to get and maintain an erection. And its located right in there close to the rectum. So, right in the middle of three really important systems.

OK. Back to your story. You’ve got the high PSA number. What’s likely to happen now?

Your general practitioner is probably going to want to refer you to a urologist. The urologist is almost certainly going to want to perform a needle biopsy and usually right away. It’s cancer! There’s urgency! Right?  Ummm. Not really. But we’ll get to that in a future video. For now, just know that for the overwhelming majority of men prostate cancer is very slow growing. You have time.

Here’s your first step in taking control. That’s what this is all about. Taking control of your own healthcare.

Unless your PSA number is crazy high (above 20 for example) or your GP has felt that something is wrong during the Digital Rectal Exam or DRE (that’s the finger up your butt exam that we all adore), you need to tell him or her that you want another PSA test. You see, that test measures a substance in the blood that the prostate gives off when it’s aggravated, and it can be aggravated by quite a few things other than cancer. Sexual activity, inflammation, certain types of heavy lifting, even riding a bike. So you’ll want to wait a few weeks, take it easy for the last few days, refrain from sex for 48 hours (you can do it), and retake the test. If your number has gone back down to near its normal level, you’re done for now. Just make sure to keep getting those yearly PSA tests and DREs.

If it remains high, then its time to move to the next step. Biopsy, right?

Nope. Not if you can help it.

The random needle biopsy, as it’s called, involves sticking a rather large needle into the area just in front of the rectum 12 times to remove samples, called cores, from different areas of the prostate.

It sounds horrible but, to be honest, it’s not terribly painful and it’s usually over in 10 or 15 minutes. A visit to the dental hygienist is probably just as uncomfortable. But it is invasive. Three percent of the men undergoing needle biopsies get infections, some of which are very serious. More importantly though, is the fact that the random needle biopsy is not very accurate. It can miss serious cancer or it can pick up low level, non-aggressive cancers that really don’t require treatment. (We’ll talk about the types of prostate cancer in a future video.)

The doctors who use the random needle biopsies don’t do it because they are mean or ignorant…maybe just a little slow to change. Until the last couple of years the needle biopsy was the best diagnostic tool that we had. Recent advances in MRI imaging have changed everything. The latest generation of MRI machines called 3 Tesla, or 3T machines, scan at a much higher resolution than the earlier machines. They enable radiologists to see all but the tiniest tumors. The tumors that they can’t see almost certainly don’t matter.

What improvements in imaging mean is that biopsies, when they are needed, can be targeted, right to the suspicious area in the prostate. No more random poking.

So, to summarize. If your PSA number comes back high:

Schedule a second PSA test.
Start doing some research. A good place to start is PCRI.org.
If the number is still high after that test, find an MRI center that does “Multi-parametric” testing using a 3T scanner (a list of 3T MRI centers is available at PCRI.org). The MRI report will provide two types of important information:

The MRI measures the size of the prostate. The scan report will enable you to determine if your PSA elevation is proportionate to your prostate size. We’ll talk about this more in a future video. As regards cancer,  there are three possible outcomes:

No high grade cancer. Further monitoring without biopsy is OK.
A high-grade lesion is detected.  Targeted biopsy is needed.
An ambiguous area is detected.  Another MRI in 6 months may be appropriate.

Scanning the prostate in men with PSA elevation is a brand new approach that is more reliable than the old-fashioned method of using 12 random needle sticks. However, this claim is only accurate when using the very latest state-of-the-art MRI technology at approved centers. This technology is so new that finding doctors willing to abandon the old random needle biopsy approach is still a major challenge.  Even so, there is a big payoff, being able to bypass those needles, those infections, and the inaccuracy is worth it.


picjumbo.com_HNCK8984.jpg

Clinical Trials


Clinical trials, also called clinical studies, test new methods to treat, diagnose, and prevent cancer. Only treatments that provide promising results in laboratory tests advance to clinical trials.

Clinical Trials


Clinical trials, also called clinical studies, test new methods to treat, diagnose, and prevent cancer. Only treatments that provide promising results in laboratory tests advance to clinical trials.

 

CLINICAL TRIALS

 

PHASE III TRIALS: Phase III clinical trials build upon evidence of effectiveness in previous Phase I & II trials in small samples, and expand to a larger sample in an attempt to confirm the experimental treatment's efficacy. This also applies to investigation of an existing treatment (or treatment combination) not previously examined in a particular category of disease. Treatments investigated in Phase III trials have stronger evidence of effectiveness than in previous phases.

PHASE II TRIALS: Build upon evidence of safety from previous Phase I trials that indicate the relative safety and appropriate dosing of a new agent.  Once the Phase I trial demonstrates the appropriate dosage, the Phase II trial can commence to study the new agent in a single type of cancer to determine the response rate of the new agent.  So the advantage to the patient for a Phase II trial is that 100% of the men involved in the trial get the new agent.  No placebos are involved.  The disadvantage is that the effectiveness of the new agent is still being tested so it is often impossible to know what the response rate will be for any specific patient contemplating embarking on a Phase II trial.

PHASE I TRIALS: Are performed primarily to determine the safe dosage of a brand new agent that has never been administered to humans before. Phase I trials start at a small dose and with successive patients who are accrued to the trial, the dosage is slowly escalated.  The trial ends when men start encountering unacceptable toxicity. Phase I trials are only for men who are very desperate or for the rare situation when clear cut responses have been reported with the men previously treated at lower doses with the same agent.  


PHASE III TRIALS


ARAMIS (BAY1841788 | ODM-201) 

A new oral medication called ARAMIS is being evaluated in men who have rising PSA levels on Lupron and whose bone scans remain clear.  For more information, visit: https://clinicaltrials.gov/show/NCT02200614

ARAMIS is similar to Xtandi but may have some advantages because ARAMIS is less likely to affect brain function which could reduce the likelihood of seizures and side effects such as fatigue which are potential side effects from Xtandi.  Two out of every 3 men in this study will be randomly assigned to receive investigational medication. 

The purpose of the study is to determine the safety and efficacy of ARAMIS in delaying prostate cancer from spreading outside of the prostate. 

To be eligible to participate in the trial men must: 

  • Have a PSA rising quickly enough to double in less than 10 months
  • No previous treatment with Xtandi or Zytiga
  • No prior chemotherapy or immunotherapy for prostate cancer.
  • Overall reasonably good health without serious heart problems.

If you are currently receiving hormone therapy, your treatment will continue and in addition you will receive either the investigational medication or placebo. Two out of every 3 patients will receive investigational medication and the assignment to the medication will be random. 

The purpose of the ARAMIS trial is to determine the safety and effectiveness of ARAMIS to delay prostate cancer from spreading. 

Talk with your doctor to find out if joining a clinical trial is right for you.

To learn more about the ARAMIS trial and to find out if you may be eligible to participate in the study, please visit:  http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php (Trial Number: 17712) or https://clinicaltrials.gov/ct2/show/NCT02200614?term=ARAMIS&rank=2  (Study Identifier: NCT02200614) or contact Bayer Oncology Clinical Trial Navigation Service 844-229-3710 (toll free) www.oncologytrials.bayer.com

 

XTANDI COMPARED TO OLDER PILLS SUCH AS CASODEX AND FLUTAMIDE

Enzalutamide (Xtandi) in First Line Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer. For more information, visit: https://clinicaltrials.gov/show/NCT02446405

This Phase III trial is testing the premise that earlier use of a more potent agent (Xtandi) will translate into improved survival.  Presently, for insurance reasons, access to Xtandi prior to the onset of hormone resistance is limited. Many experts believe, however, that early use of the most effective agent translates into improved survival.  This trial can benefit patients who have no potential access to the early use of Xtandi as it gives the participants a 50% chance they will receive the Xtandi free of charge.  

Experimental agent: Enzalutamide (Xtandi) may reduce tumor cell growth by blocking androgen receptors.
Purpose: Compare overall survival time between Enzalutamide and other anti-androgens.
Arm A: Enzalutamide + LHRH analogue (e.g. Lupron)
Arm B: Non-steroidal anti-androgen (e.g. Nilutamide, bicalutamide flutamide) + LHRH Analogue
Notable eligibility criteria:
- Metastatic disease
- No prior chemotherapy - exception: up to 2 cycles of Docetaxel for metastatic disease
- No history of seizure or conditions that predispose to seizure
- No history of Transient Isquemic Attacks

 

DENDRITIC CELL VACCINE

Phase III Study of DCVAC Added to Standard Chemotherapy for Men with Metastatic Castration Resistant Prostate Cancer (VIABLE). For more information, visit: https://clinicaltrials.gov/show/NCT02111577

Immune therapy is becoming more mainstream in prostate cancer, lung cancer and melanoma.  Generally the side effects are quite minimal compared to other types of therapy.  This trial adds immune therapy to standard Taxotere chemotherapy to determine if the immune treatment improves response rates and survival.  Since this form of immune therapy is not yet FDA approved this trial is the only way for patients to access the drug.  

Experimental agent: Dendritic cell vaccine (DCVAC/PCa) may destroy tumor cells by stimulating a cytotoxic T-lymphocyte (CTL) response against PSA-expressing cancer cells.
Purpose: Evaluate overall survival time under dendritic cell vaccine when combined with Docetaxel.
Arm A: Dendritic cells vaccine + Docetaxel (Taxotere)
Arm B: Placebo + Docetaxel
Notable eligibility criteria:
- Castrate-resistant metastatic disease
- No prior chemotherapy
- No prior immunotherapy within 6 months

 

XTANDI

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)
For more information, visit: https://clinicaltrials.gov/show/NCT02003924 | Click here for a patient brochure of this trial. 

Xtandi is FDA approved for men with hormone resistance who have already developed metastases.  However, insurance coverage is often denied for men with hormone resistance who are yet to develop metastases.  The advantage for patients in this trial is the earlier exposure to a potent agent like Xtandi at a time before the disease has progressed to overt metastases may be advantageous.

Experimental agent: Enzalutamide (Xtandi) may reduce tumor cell growth by blocking androgen receptors.
Purpose: Assess the effectiveness (survival time without metastatic progression) of Enzalutamide in nonmetastatic disease.
Arm A: Enzalutamide
Arm B: Placebo
- Castrate-resistant disease WITHOUT metastases
- PSA doubling time ≤ 10 months
- No prior hormonal therapy except for LHRH therapies (e.g. Lupron, Eligard)
- No prior chemotherapy

 

ORTERONEL (TAK-700)

Phase III Lupron+TAK-700 vs. Lupron+Bicalutamide for Metastatic, Hormone-Sensitive Prostate Cancer (SWOG 1216)
For more information, visit: https://clinicaltrials.gov/show/NCT01809691

Bicalutamide (Casodex) is generally the standard first step when Lupron stops working.  However, Bicalutamide is a relatively weak agent. TAK-700 is more potent than Bicalutamide and is therefore likely to be more advantageous.  TAK-700 is not yet approved by the FDA and is only available via a clinical trial such as this. 

Experimental agent: Orteronel (TAK-700) may suppress androgen-dependent tumor cell growth by inhibiting the 17,20 lyase steroid in the testes and adrenal glands.
Purpose: Compare overall survival time between TAK-700 (experimental) and Bicalutamide (established).
Arm A: ADT (equivalent of Lupron) + TAK-700
Arm B: ADT + Bicalutamide (Casodex)
- Metastatic disease
- No prior chemotherapy (neoadjuvant/adjuvant use allowed if > 2 years prior)
- No prior androgen deprivation therapy within 6 months (adjuvant/neoadjuvant use OK if total treatment < 36 months)
- No prior Ketoconazole, Aminoglutethimide, Abiraterone, or Enzalutamide

 


HORMONE SENSITIVE, LOCALIZED NON METASTATIC DISEASE

PROSTATAK

Phase III Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03)
Immune therapy it believed to have greater anticancer activity when used to treat earlier, low-volume disease.  In this study men with newly-diagnosed cancer that is relatively high risk can undergo radiation with our without immunotherapy.  The hope is that the men who receive immunotherapy can benefit with improved cure rates. For more information, visit: https://clinicaltrials.gov/show/NCT01436968

Experimental agent: ProstAtak (AdV-tk) may stimulate an antitumor cytotoxic T lymphocyte (CTL) response by working in conjunction with Valacyclovir to kill tumor cells overexpressing the HSV-tk gene.
Purpose: Assess the effectiveness (survival time without disease recurrence) of combining ProsAtak, Valacyclovir, and radiation therapy with optional androgen deprivation therapy.
Enrollment: 711
Arm A: ProstAtak (AdV-tk) + Valacyclovir + radiation therapy + (optional) androgen deprivation therapy
Arm B: Placebo + Valacyclovir + radiation therapy + (optional) ADT
Notable eligibility criteria:
- Intermediate Risk disease (PSA 10-20 ng/ml, Gleason score 7, T2b-T2c)
- No more than 1 High Risk feature (PSA>20 ng/ml, Gleason score 8-10, or T3a), no metastatic disease
- No prior treatment except TURP or ADT (maximum 6 months)

 


PHASE III TRAILS | ONGOING BUT NOT RECRUITING


XTANDI WITH ZYTIGA 

Enzalutamide (Xtandi) With or Without Abiraterone (Zytiga) and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer. For more information, visit: https://clinicaltrials.gov/show/NCT01949337 

Xtandi and Zytiga block testosterone activity within the cancer cell using distinctly different biochemical pathways.  As such, both agents in combination are likely to be more effective than either agent by itself.  However, relatively few insurance companies will pay for the use of both of these agents at the same time.  Half the men in this study will receive a combination of both agents with the cost being borne by the company sponsoring the trial. 

Experimental agent: Enzalutamide (Xtandi) may reduce tumor cell growth by blocking androgen receptors.
Abiraterone (Zytiga) may suppress testosterone production by inhibiting activity of the CYP17 enzyme.
Purpose: Evaluate overall survival time under Enzalutamide when combined with Abiraterone.
Arm A: Enzalutamide
Arm B: Enzalutamide + Abiraterone
Notable eligibility criteria:
- Castrate-resistant metastatic disease
- No prior Abiraterone, Enzalutamide, or any chemotherapy
- No history of seizure or related conditions
- No history of TIA within 12 months

 

ARN-509

A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN). For more information, visit: https://clinicaltrials.gov/show/NCT01946204

ARN-509 is a pill with similar function to Xtandi that is being studied in men with hormone resistance who have yet to develop any metastases.  Xtandi is only approved for men with metastases so insurance coverage is often denied. The advantage for patients in this trial is the earlier exposure to a more potent agent at a time before the disease has progressed to overt metastases. 

Experimental agent: ARN-509, an androgen receptor antagonist, may inhibit tumor cell growth by inhibiting genes that regulate cancer cell proliferation.
Purpose: Assess the effectiveness (survival time without metastases) of ARN-509.
Arm A: ARN-509
Arm B: Placebo
- Castrate-resistant disease WITHOUT metastases
- No prior Abiraterone or Enzalutamide
- No prior CYP17 inhibitors
- No prior chemotherapy

 

ARN-509

An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC). For more information, visit: https://clinicaltrials.gov/show/NCT02257736

This study compares Zytiga alone with Zytiga plus ARN-509. Zytiga and ARN-509 block testosterone activity within the cancer cell using distinctly different biochemical pathways.  As such, both agents in combination are likely to be more effective than either agent by itself.  However, patients outside of this trial have no possibly opportunity of being treated with ARN-509 and Zytiga simultaneously because RN-509 has not yet been approved by the FDA. Half the men in this study will receive a combination of both agents with the cost being borne by the company sponsoring the trial

Experimental agent: JNJ56021927 (ARN-509), an androgen receptor antagonist, may inhibit tumor cell growth by inhibiting genes that regulate cancer cell proliferation.
Purpose: Assess the effectiveness (survival time without disease progression on scans) of JNJ56021927 when combined with Abiraterone.
Arm A: JNJ56021927 + Abiraterone (Zytiga)
Arm B: Placebo + Abiraterone
Notable eligibility criteria:
- Castrate-resistant metastatic disease
- No prior chemotherapy (except adjuvant/neoadjuvant use)
- No pain requiring opioids/narcotics

 


PHASE II TRIALS


XTANDI

LHRH Analogue Therapy With Enzalutamide (Xtandi) or Bicalutamide (Casodex) in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer.  For more information, visit: https://clinicaltrials.gov/show/NCT02058706

Until the relatively recent FDA approval of Xtandi for hormone resistant disease Casodex and Lupron was the only alternative.  This trial is designed to test the premise that initiating Xtandi immediately, rather than waiting for resistance to Casodex and Lupron develop, is advantageous for patients.  In this trial half the men will receive immediate Xtandi and the other half will receive the traditional combination of Casodex and Lupron. 

Agent: Enzalutamide (Xtandi) may reduce tumor cell growth by blocking androgen receptors.
Purpose: Compare the effectiveness (PSA remission) between Enzalutamide (experimental) and Bicalutamide (known) in hormone sensitive prostate cancer.
Enrollment: 92
Arm A: Enzalutamide + LHRH analogue (Lupron, etc.)
Arm B: Bicalutamide (Casodex) + LHRH analogue
Notable eligibility criteria:
- Metastatic disease
- PSA ≥ 4 ng/ml within 28 days if no prior hormone therapy
- No prior neoadjuvant/adjuvant hormone therapy within 6 months
- No prior chemotherapy or androgen synthesis/receptor blockers (Abiraterone, Enzalutamide, TAK-700, ARN-509, etc.)
- No history of seizure or conditions that predispose to seizure. 

 

PROVENGE WITH YERVOY

A Randomized Phase II Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer
Immune therapy has been the hot topic of 2015 with new and powerful agents showing dramatic activity in both lung cancer and melanoma.  One agent, Yervoy, that works by “taking the brakes off the immune system” has affected notable responses in very difficult cases of melanoma.  Yervoy has also been tested in very advanced prostate cancer and shown to have notable activity.  Combining Yervoy with Provenge, another immunotherapy that is already FDA approved for prostate cancer is a very compelling concept. Despite the fact that Yervoy can be associated with potentially severe side effects, this Phase II trial is potentially one of the most attractive trials for patient with hormone resistant disease. For more information, visit: https://clinicaltrials.gov/show/NCT01804465

Experimental agent: Sipuleucel-T (Provenge) may stimulate an antitumor T-cell response against PAP-expressing tumor cells. Ipilimumab (Yervoy) may stimulate a cytotoxic T-lymphycite (CTL)-mediated immune response against cancer cells by inhibiting the CTLA4-mediated downregulation of T-cell activation.
Purpose: Assess the impact (on immune response) of the timing of Ipilimumab following Sipuleucel-T.
Arm A: Sipuleucel-T + immediate Ipilimumab
Arm B: Sipuleucel-T + 3-week delayed Ipilimumab
Notable eligibility criteria:
- Castrate-resistant metastatic disease
- No prior chemotherapy except neoadjuvant use
- No prior Sipuleucel-T or experimental immunotherapy
- No cancer pain requiring narcotics
- No history of autoimmune disease

 

PROSTVAC

Prostvac (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance. For more information, visit: https://clinicaltrials.gov/show/NCT02326805

Agent: Prostvac-V/TRICOM is an immunotherapy vaccine that may encourage a cytotoxic T-cell immune response against PSA-expressing tumor cells.
Purpose: Evaluate response in PSA and immune indicators to Prostvac-V
Enrollment: 150
Arm A: Prostvac-V/TRICOM
Arm B: Placebo
Notable eligibility criteria:
- No prior treatment (including surgery, irradiation, local ablative, or androgen deprivation)
- No distant metastases
- No immunodeficiency or splenectomy

 

 


PHASE I and II TRAILS


ADXS-PSA 

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
For more information, visit: https://clinicaltrials.gov/show/NCT02325557

Agent: ADXS-PSA (or ADXS31-142), an immunotherapy, may drive an immune response to PSA-expressing cells by targeting prostate-specific antigen (PSA) associated with prostate cancer.
Pembrolizumab (Keytruda) may activate T-cell-mediated immune responses against tumor cells by binding to and inhibiting the programmed cell death-1 (PD-1) protein.
Purpose: Assess the safety and effectiveness (survival without disease progression) of immunotherapy ADXS-PSA.
Enrollment: 51
Part A (Phase I): ADXS-PSA
Part B (Phase I-II): ADXS-PSA + Pembrolizumab
Notable eligibility criteria:
- Castrate-resistant metastatic disease
- No more than 3 prior treatment (chemotherapy, hormonal, or immunotherapy) in metastatic setting
- No more than 1 chemotherapy in metastatic setting
- No active autoimmune disease requiring systemic treatment within the past 2 years


OTHER STUDIES


Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

The purpose of this registry is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management. Unlike clinical trial studies, registries are not designed to test potential new medical treatments. They simply collect information about treatments that are already being used, allowing doctors to see how well they work in a “real-world” setting of care.  

This observation study will look at how doctors’ decisions and the treatments they prescribe affect the day-to-day lives of the men who receive them. We hope this information may help improve the care of men with advanced prostate cancer in the future. The TRUMPET Registry is for men whose prostate cancer progressed (i.e. it has grown or spread) despite use of hormonal treatments to lower their PSA.  Known as castration-resistant prostate cancer, this disease progression may require different treatment options, which can be discussed with the treating physician. Upon enrolling in TRUMPET, information will be confidentially collected at routine medical visits and through health surveys.

Notable eligibility criteria:

- Confirmed diagnosis of CRPC

- Patients may be enrolled within 90 days from the time of decision to treat or within 90 days of treatment initiation.

- Initiating the first or second line treatment for CRPC

To inquire about registering at participating study centers, please contact Astellas Scientific & Medical Affairs by calling (800) 888-7704, extension 5473, or emailing Astellas.registration@astellas.com. For more information, visit: https://clinicaltrials.gov/show/NCT02380274

 

 
adrian-161202.jpg

Support Groups


If you are dealing with prostate cancer, you need not be alone.

A support group can provide a continuing opportunity to learn about the various aspects of the disease, and to share experiences and feelings with others. Most meetings provide an educational program presented by a professional in the field followed by an open discussion session. Partners are encouraged to attend most groups. Some have a separate meeting for partners during part or all of the session. For additional information, contact the following groups.

Support Groups


If you are dealing with prostate cancer, you need not be alone.

A support group can provide a continuing opportunity to learn about the various aspects of the disease, and to share experiences and feelings with others. Most meetings provide an educational program presented by a professional in the field followed by an open discussion session. Partners are encouraged to attend most groups. Some have a separate meeting for partners during part or all of the session. For additional information, contact the following groups.

UNITED STATES


ALABAMA

Birmingham | UsTOO St. Vincents East | 44 Medical Park East 35235 | 2nd Wed. 12pm | Debbie Gray | 205-838-3724 | debbie.gray@stvhs.com

ALASKA

Anchorage | UsTOO Anchorage Chapter | Providence Cancer Center Tower U | 1st Tues. 6pm | Dave Grashin | 907-250-6878 | dgrashin@gmail.com

ARIZONA

Scottsdale | UsTOO 21st Century Oncology | 7340 East Thomas Road | 2nd Mon. 7pm | John Sizer | 602-369-5225 | jsizer@cox.net

Chandler | UsTOO Southeast Valley | Ironwood Cancer Research Center | 695 S. Dobson Road | 2nd Mon. 7pm | Otto Sankey | 480-229-5837 | ottosankey@hotmail.com 

Sierra Vista | UsTOO Dr. John B. Sawyer Chapter | The Wellness Depot @ Sierra Vista Mall | Last Fri. 9am (No meeting Nov. & Dec.) | Robert Norquist | 520-803-6773 | ustoosvaz@gmail.com

ARKANSAS

Conway | Conway Peer Network Meeting | First United Methodist Church, 1610 Prince Street, Room 217 | 3rd Thurs. 6pm | Bev Eckert | 501-379-8027

Fort Smith | Fort Smith Peer Network Support Group | Reynolds Cancer Support House, 3324 South M Street | Every Wed. 6pm | Bev Eckert | 501-379-8027

Jonesboro | Jonesboro Peer Network Support Group | Second Floor, UAMS Center on Aging, 303 East Matthews | 1st Thurs. 6pm | Bev Eckert | 501-379-8027

Little Rock | Little Rock Peer Network Support Group | Second Presbyterian Church, Room 67 | 600 Pleasant Valley Drive | 2nd Tues. 6pm | Bev Eckert | 501-379-8027

Springdale | Peer Network Support Group | Springdale Country Club, 608 West Lakeview Drive, Dogwood Room | 3rd Tues.6pm | Bev Eckert | 501-379-8027

 

CALIFORNIA

Palm Desert | Viviendo con Cancer | Gilda’s Club Desert Cities, 73555 Alessandro Drive | Jueves 6pm | Lucy Gutierrez, MSW | 760-770-5678

Palm Desert | Familiares y Amigos | Gilda’s Club Desert Cities, 73555 Alessandro Drive | Jueves 6pm | Carmen Mendoza, MSW | 760-770-5678

Cameron Park | UsTOO Eldorado County | Marshall Medical Cancer Center 3581 Palmer Drive Suite 400 | 1st Thurs. 3pm | Richard Montgomery | 916-213-5593 | richardmontgomery773@gmail.com

Fontana | UsTOO Kaiser Permanente | Medical Office Bldg 2 | 4th Wed. 7pm (No meeting Nov. & Dec) | Janis Snarr Garcia | 909-427-5411

Fountain Valley | Walnut Gang | Orange Coast Memorial Hospital 18111 Brookhurst Street, Fourth Floor Conf. Room | Larry Gerber | 714-408-8316 | largerb1@aol.com

Fresno | UsTOO Urology Associates & Fresno Center | 7887 North Cedar Avenue | 3rd Tues. 6:30pm | Judy Burden | 559-437-1000 | jburden@uscmc.com

Fullerton | Prostate Forum of Orange County | First Presbyterian Church 838 North Euclid | 2nd Thurs. 11:30am, 4th Thurs. 5pm | Russell Thomas  | 951-545-1616 | russaree@yahoo.com

Long Beach | UsTOO Long Beach Memorial Medical Center at Todd Cancer Institute | 4th Tues. 6:30pm | Charles Kokaska, MD | 562-426-5250 | chaskaska31@yahoo.com

Modesto | UsTOO McHenry Center | 1700 McHenry Blvd Suite 60B | 4th Mon. 6:30pm | Ken Willmarth | 209-521-6468 | kenwillmarth@gmail.com

Monterey | PC Self Help Group of CA Center Coast | 100 Barnet Segal Lane | 1st Wed. (every other month starting Feb.) | Pat Soifer | 831-373-5531 

Mountain View | UsTOO Silicon Valley | El Camino Hospital Conference Rooms E, F, & G | 1st Thur. 5pm (Advanced group), 7pm (General) | Frank Weiss | 650-969-1939 | frankweiss@aol.com

Newport Beach | Hoag Memorial Hospital PC Group | 1 Hoag Drive, B41 | 1st Wed. | Sandy Pollet | 949-764-1804 | sandy.pollet@hoag.org  

Oakland | UsTOO Markstein Cancer Education Ctr | 3100 Summit Street (Lobby Level) 94609 | 2nd Tues. 6:15pm (Younger men), Last Tues. 6:15pm (General) | Leslie Paine | 510-869-8823

Orange | St. Joseph's Hospital | Cancer Center, second floor | 3rd Tues. (even months only) 6pm | Enza Esposito-Nguyen | 714-734-6237

Pasadena | COPE | Huntington Cancer Center, conference room | 1st Thurs. 5pm | Mays Chua | 626-397-5071 | mays.chua@huntingtonhospital.com 

Pomona | Robert-Beverly Lewis Cancer Center | Mary Dyer | mary.dyer@pvhmc.org

Redondo Beach | Wellness Community | 109 West Torrance Blvd | 1st Thurs. + 3rd Wed. 4:30pm | Stephen Lottenberg | 310-376-3550 | twcsbc@aol.com

Ridgecrest | UsTOO Indian Wells Valley | David Mechtenberg Conference Center | 3rd Mon. 7pm | Marc Moulton | 760-375-5364 | marc@msmoulton.com

Riverside | Men & Prostate Cancer - Riverside Medical Foundation | Conference Room 1 & 2, 7117 Brockton Ave. | 2nd Thurs. 7pm (except Dec.) | Erin Lang | 951-682-2753 | Erin@rmccharity.org

Sacramento | UsTOO | Alternates between locations, UC Davis Comprehensive Cancer Center + Mercy San Juan Medical Center | 3rd Thurs. | Beverly Nicholson | 916-537-5237 | beverlynicholson@comcast.net

Santa Barbara | Cancer Center of Santa Barbara w/ Sansum Clinc |  317 West Pueblo Street, Conference Room | 2nd Mon. 2pm | Mary Solis, LCSW | 805-682-7300

Santa Barbara | UsTOO Cancer Foundation | 300 West Pueblo Street | Mary Solis, LCSW | 805-569-7406 | mary@ccsb.org

Santa Cruz | UsTOO Katz Cancer Resource Center | Education Building Room F 1555 Soquel Drive | Last Tues. 7pm | Howard Wage | 831-688-0423 | laselvaman@hotmail.com

Santa Monica | CSC | 1990 South Bundy Drive, Suite 100 | 2nd Mon. 6pm | Bill Kavanosh | 310-314-2555 x 2594 | info@twc-wla.org

San Diego | Informed Prostate Cancer Support Group | 3rd Sat. 10am | Sanford Children's Health Research Center Auditorium, 10905 Road to the Cure | Lyle LaRosh | 619-890-8447 | info@IPCSG.org

San Francisco | St. Francis Memorial Hospital | Radiation Oncology Dept. 900 Hyde Street | 1st Wed. 7pm | Michael Staples | 415-353-6780 | michael.staples@dignityhealth.org

San Fernando Valley | UsTOO Our Redeemer Lutheran Church South Hall | 8520 Winnetka Avenue | 1st Mon. 6:30pm | Phil Dipaola | 818-618-7700 | phil@menstherapist.com

San Rafael | UsTOO Marin | Marin General Hospital Staff Medical Library | Every Tues. 7pm | Stan Rosenfeld | 415-459-4668 | vegstan2@ix.netcom.com

San Ramon | UsTOO San Ramon Medical Center | South Building West Day Room 7777 Norris Canyon Road | 2nd Tues. 7:30pm

Sherman Oaks | UsTOO We Speak | Mark Landow | 818-901-9901 | landowshrm@aol.com

Simi Valley | UsTOO Simi Valley Senior Citizen's Center | 3900 Avenisa Simi | 3rd Tues. 7pm | Dave Middleton | 805-526-7255 | dsan007@att.net

Walnut Creek | UsTOO The Wellness Community | 3276 McNutt Avenue | 4th Thurs. 11am (Advanced Only), 1pm (General group) | Ron Ellis, PhD | 925-933-0107 | rellis6958@sbcglobal.net

Walnut Creek | Wellness Community | 3276 McNutt Avenue | Last Thurs. 1pm (except Nov.) | Judy Blazin | 925-933-0107

Westlake Village | UsTOO Westlake Cancer Support Community | 530 Hampshire Road | 3rd Sat. 10:30am, 2nd + 4th Wednesday 6:30pm | Kevin Axelrad | 310-393-2186 or 805-379-4777 | axelradk@roadrunner.com

Woodland Hills | Kaiser Permanente 5601 De Soto Avenue | John Faas, LCSW | john.w.faas@kp.org

Ventura | Community Memorial Hospital | CMH Cancer Resource Center 2900 Loma Vista Road Suite 105 | 2nd Thurs. 6:30pm | Helmet Hoenigsberg| 805-652-5459

COLORADO  

Boulder | UsTOO | 4th Tues. 6pm | Rick Powers | 303-442-5679 | boulderpces@gmail.com

Fort Collins | UsTOO | Colorado Health Medical Group Urology 2315 East Harmony Road Suite 140, Conf. Room | 2nd Tues. 6pm | Robert Omodt | 970-282-0582 | romodt@yahoo.com

CONNECTICUT 

Danbury | UsTOO Men Together | Ann's Place 80 Saw Mill Road | 1st Wed. 6:30pm | Sue Murdock | 203-790-6568 | su_annsplace@sbcglobal.net

DELAWARE

Dover | BayHealth | Alternate sites, Kent General Hospital Dover (odd months, ex. Jan, March...), Milford Memorial Hospital (even months) | 3rd Wed. 7pm | Paula Hess, RN | 302-430-5064 | paula_hess@bayhealth.org

Dover | CSC | 812 South Bradford Street | 3rd Wed. 7pm | jshallcross@cscde.org | phone: 302-734-0898

Wilmington | CSC | 4810 Lancaster Pike | 3rd Mon. 6:30pm | npickles@cscde.org | Phone: 302-995-2850 

FLORIDA

Miami | CSC | Grupo de Apoyo | 8609 South Dixie Highway | Thurs. 10am| info@cancersupportcommunitymiami.org | 305-668-5900

Fort Lauderdale | CSC - Gay Men’s Support Group | 119 Rose Drive | 2nd Monday 5:30pm | 954-763-6776  

Fort Lauderdale | CSC - Men’s Club | 119 Rose Drive | 2nd Sat. 10am + 4th Mon. 5:30pm | 954-763-6776 

Fort Walton Beach | Fort Walton Beach Medical Center, 1000 Mar Walt Drive | 2nd Thurs. 7pm | Tom Alexander | 850-651-2326 | talex5@cox.net

Margate | Aaron Neuhaus Memorial Chapter  | Northwest Medical Park Building Suite 104, 2960 NW Street Road 7 | 2nd Mon. 7:30pm | Marvin Stein, MD | 954-979-2444 | stoneman12md@netscape.net

Panama City | UsTOO Emerald Coast PCa Survivors | Holy Nativity Episcopal Parish House, 1011 East 3rd Street | 2nd Tues. 5:30pm | Rick Watson | 850-625-0847 | rickwatson9@yahoo.com

Sarasota | UsTOO | Doctors Hospital Cattleman and Bee Ridge | 3rd Thurs. 6pm | Steve Gordon | 941-374-0990 | ustoosarasota@yahoo.com

The Villages | Village Prostate Cancer Group | The Laurel Manor Recreation Center, 1985 Laurel Manor Drive | 1st Wed. 7pm, 3rd Wed. 7pm (odd months, ex. Jan., Mar...) | Dan Bard | 352-391-2035 | dpbinfl@aol.com

West Palm Beach | UsTOO Wellington Regional Medical Center | 1st Thurs. 7pm | Jesse Seligman | 561-963-3412 | jessel100@comcast.net

GEORGIA

Athens  | UsTOO | Loran Smith Center, 240 Talamadge Drive | 2nd Thurs. 7pm | Tom Stephens | 770-403-0257 | stephens3954@yahoo.com 

Atlanta | Cancer Support Community Atlanta | 5775 Peachtree Dunwoody Road, Building C, Suite 225 | (Starting in May 2017) 4th Mon. 10:30am | Rachel Newby | rachel@cscatlanta.org | 404-843-1880

Augusta | UsTOO | Cancer Center Georgia Health Sciences Institute, 1499 Laney Walker Blvd | 3rd Tues. 7:30pm (No meeting June & July) | Terry Leiden | 706-724-8548 | tleiden@leidenandleiden.com

Fayetteville | UsTOO | Piedmont Fayette Hospital | Jim O'Hara

Johns Creek | UsTOO | Johns Creek United Methodist Church, Room 201, 11180 Medlock Bridge Road | 3rd Tues. 7pm | William Neils | 770-783-2502 | wneils@yahoo.com 

Marietta | UsTOO Wellstar and American Legion Post 29 | Radiation Conference Room, Lower Level, Kennestone Cancer Center, 320 Kennestone Hospital Blvd | 2nd Thurs. 7pm | Gigi Bellamy | 770-793-7465 | glinda.bellamy@wellstar.org

HAWAII 

Hilo | UsTOO East Hawaii | Church of the Holy Cross, 400 West Lanikaula Street | 3rd Fri. 7pm | Paul Mizue | 808-222-0425 | hpm@hawaii.rr.com 

Honolulu | UsTOO Pali Momi | Kapiolani Medical Center at Pali Momi-Ewa Conference Room | 3rd Fri. 7pm | Paul Mizue | 808-222-0425 | hpm@hawaii.rr.com 

 

ILLINOIS 

Chicago | UsTOO/Gilda's Club River North | 537 North Wells Street | 3rd Thurs. 6pm | Jim Schraidt | 312-327-1392 | jschraidt@skcounsel.com

Chicago | UsTOO | University of Chicago/Weiss Memorial Hospital | 2nd Tues. 6pm | Michael Sinner | 773-564-5355Geneva | UsTOO | Living Well Cancer Resource Center, 442 Williamsburg Avenue | 3rd Tues. 10:30pm | Don Shank | 847-695-3200 x5807 | donshank@presencehealth.org 

Elgin | UsTOO Presence St. Joseph Hospital | Meadows Cancer Center, 77 North Airlite | 4th Tues. 7pm | Don Shank | 847-695-3200 x5807 | donshank@presencehealth.org 

Elgin | UsTOO Presence St. Joseph Hospital | Meadows Cancer Center, 77 North Airlite | 1st Tues. 10am (Mets Group) | Don Shank | 847-695-3200 x5807 | donshank@presencehealth.org

Elgin | UsTOO Presence St. Joseph Hospital | Meadows Cancer Center 77 North Airlite | 2nd Tues. 10am | Don Shank | 847-695-3200 x5807 | donshank@presencehealth.org

Evanston | NorthShore University Health System | Jeffrey Albaugh, PhD | Director of Sexual Health

Hinsdale | Wellness House PCa Support Group | 131 North County Line Road | 2nd Wed. 9:30am | Michael Williams | 630-654-5117 | mwilliams@wellnesshouse.org

Moline | UsTOO Greater Quad Cities | Trinity Medical Center 17th Street, Conference Room Rock Island, 1st Floor | 3rd Thurs. 7pm | Bill Palos | 309-799-3621 | wpalos@aol.com

Peoria | UsTOO | Proctor Professional Building 1, 5401 North Knoxville Avenue | 4th Tues. 7pm (only Jan, April, July, Oct.) | George Melton | 309-691-6523 | geosara517@gmail.com

Springfield | UsTOO | Memorial Medical Center, 149 Springfield, Conference Room B | 2nd Wed. 5:15pm | Charlene Vollmer | 217-891-2981 | charlene.vollmer@gmail.com

INDIANA

Fort Wayne | UsTOO | Cancer Services Facility, 6316 Mutual Drive | 1st Wed. 6:30pm (advanced/recurring) | Bill Seidel | 260-437-9670 | bseidel22@comcast.net

Fort Wayne | UsTOO | Cancer Services Facility, 6316 Mutual Drive | 1st Thurs. 6:30pm | Bill Seidel | 260-437-9670 | bseidel22@comcast.net

Marion | Cancer Services of Grant Count | Jennifer Lane-Riefler (contact for support meeting details) | 765-664-6815 | execdirector@grantcountycancer.org

IOWA 

Cedar Rapids | General Cancer Support Group | Halle Perrine Cancer Center, 701 10th Street Southeast, Community Room A + B | 1st + 3rd Tues. 5:30pm (general) | Peggi Weston-Kolarik | 319-221-8405 | peggikolarik@mercycare.org

Des Moines | UsTOO | John Stoddard Cancer Center, Unity Point Health, 1221 Pleasant Street, Suite 450 | 4th Tues. 5:30pm | Angela Dotson | 515-241-4231 | angela.dotson@unitypoint.org

Quad Cities Region | UsTOO | Trinity Medical Center, 17th Street Conference Room Rock Island, 1st Floor | 3rd Thurs. 7pm | Bill Palos | 309-799-3621 | wpalos@aol.com

KANSAS

Lawrence | Prostate Cancer Support Advocates | 325 Maine Street | 1st Tues. 5:30pm | Guy Dresser | guy.dresser@gmail.com

Wichita | UsTOO | St. Joseph's Hospital, McNamara Conf. Room,  3600 East Harry | 2nd Mon. 7:30pm | Harold Ruhl | 316-838-0209 | pros8tate@aol.com

KENTUCKY

Ashland | Man to Man | Our Lady of Bellefonte Hospital, Bellefonte Centre, 5th floor, 1000 Ashland Drive | 2nd Tues. 5:30pm | Barb Fitzpatrick | 606-833-2273

Lexington | UsTOO of the Blue Grass | St. Joseph Hospital Cancer Resource Center, 701 Bob-O-Link Drive, Suite 250 | 3rd Thurs. 6:30pm | Don Lynam | 859-221-9804 | d.lynam@twc.com

Louisville | Prostate Cancer Support Group | Medical Towers South, 234 East Gray Street, Suite 164 | 2nd Mon. 6pm | 502-629-5500

Louisville | UsTOO | Jewish Hospital | 2nd Wed. 12:30pm | Donald Stern | 502-895-9744 | dstern800@gmail.com

LOUISIANA

Tulane | Prostate Cancer Support and Discussion | tulaneurology.com/supportgroup | 504-988-5271

MAINE

Brunswick | UsTOO | Mid-Coast Hospital, 123 Medical Center Drive | 3rd Tues. 6:30pm | Terry Kungel | 617-449-8522 | tkungel@hughes.net

MARYLAND

Bethesda | UsTOO | Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, River Conference Room, 3rd Floor, Building 19 | Quarterly & Monthly Meetings available, call for details | James Thompson | 715-760-2702 | cw5t0406 @gmail.com 

Clinton | UsTOO | Colony South Hotel Route 5, Surrats Road | 2nd Tues. 6:30pm | Ed Jones | 715-760-2702 | edwjones@verizon.net

MASSACHUSETTS

Boston | UsTOO | Beth Israel Deaconess Medical Center | 1st Mon 6pm (sub-groups), 7pm (main group) | Stan Klein | 617-625-4875 | klein@rcn.com 

Lowell | UsTOO | Lowell General Cancer Center, 295 Varnum Avenue | 2nd Tues. 6:30pm | Meg Lemire-Berthel, MSW | 978-937-6142 | margaret.lemire-berthel@lowellgeneral.org

South Weymouth | South Shore Hospital Prostate Cancer Support Group | South Shore Hospital Cancer Center, 1st Floor | 2nd Wed. 7pm, 1st Sat. 9am | Michael Gutierrez | 781-624-4793 | michael_gutierrez@sshosp.org

Winchester | Winchester Hospital Prostate Cancer Support Group | 620 Washington Street, 1st Floor, Conference Room A 1080 | 1st Wed. 7pm | Gary Halvorsen | 781-272-2546 | halvy49@gmail.com

Worcester | Worcester Prostate Cancer Education & Support Group | UMASS Medical Center, ACC Building, 6th Floor | 2nd Thurs. 6pm | Carlton Barstow | 508-835-3390 | cbarstow46@gmail.com

MICHIGAN

Ann Arbor | Independent Prostate Cancer Support Group | St. Joseph Mercy Hospital-Education Center, Room 5 | 3rd Thurs. 7pm Mary-Kay Abraham, RN | 734-712-6569 | mary.abraham@stjoeshealth.org

Ann Arbor | Cancer Support Community of Greater Ann Arbor | 2010 Hogback Road, Suite 3 | 1st Wed. 6pm | 734-975-2500

Flint | UsTOO | McLaren Hospitality House, 3160 Beecher Road | 1st Tues. 7pm (No meeting, July & Aug) | Reg Tidal | Regtidball@att.net

Jackson | UsTOO Greater Jackson | Allegiance Health Hospital, 205 North East Avenue, 2nd Floor, Dining Room 1 | 3rd Tues. (Only Sept. - May) 7pm | Dale Cryderman | dlc150@yahoo.com

Lansing | UsTOO PC Support Group of Mid-Michigan | Sparrow Professional Building, 1200 East Michigan Avenue, 2nd Floor | 1st Thurs. 7pm | Deb Batterbee | 517-364-3849 | debra.batterbee@sparrow.org

Livonia | UsTOO | St. Mary Our Lady of Hope Cancer Center, 36475 Five Mile Road, (In Hospital) | 4th Wed. 7pm (Call/email for Nov. & Dec. meeting info.) | Jerry Hardy | 313-585-1641 | motownjerrylee@aol.com

Mt. Clemens | UsTOO Macomb Chapter | Ted B. Wahby Cancer Center, 1080 Harrington Road, Conference Room | 4th Wed. 6pm | Leah McLean, LMSW | 586-493-7506 | lmclean@mcrmc.org

Owosso | UsTOO | 1480 North M-52 Campus, Cancer Center, Conference Room C | 3rd Mon. 7pm | Glenn Toby | 989-743-4619 

Traverse City | UsTOO | Munson Community Center, Room A & B | 4th Tues. 6pm | Donna Hollister, RN | 231-935-0322 | dkhrn44@aol.com

MINNESOTA 

Brained | UsTOO | St. Joseph's Hospital | 2nd Tues. (call for details) | 218-828-1418

Grand Rapids | Grand Rapids PCa Support & Educational Group | Itasca Medical Center, Oak Room | 2nd Tues. 5:30pm | Tarry Edington | 218-999-9384 | tarryedington@msn.com

Minneapolis | Prostate Cancer Support Group | University of Minnesota, Hope Lodge 2500 University Ave. | 2nd Thurs. 6pm | Steve Roecklein | 612-789-1072 | sroecklein@yahoo.com

Moorhead | UsTOO Fargo | Bethesda Lutheran Church, 401 40th Avenue South | 4th Tues. 7pm | Theresa Kolle, RN | 218-233-1176 | theresakolle@msn.com

Robbinsdale/Minneapolis | UsTOO | North Memorial, 3300 Oakdale Avenue, Main Building, Plaza level, Room "Vance Delong" | 4th Wed. 5:30pm (no meeting July & Aug.) | Steve Roecklein | 612-789-1072 | sroecklein@yahoo.com

St. Cloud | UsTOO | Michael's Restaurant, 510 South Highway 10, Herberger Room | 4th Tues 5:30pm (no meetings, June/July/Aug)  | John Wolfe |  320-259-1411 | john.wolfe@centracare.com

MISSOURI

Kansas City | The Prostate Network | Gilda's Club, 100 West 43rd Street | 3rd Wed. 6:30pm | Mike Mulcahy | 913-638-7781 | mikecmulcahy@hotmail.com

St. Louis | UsTOO Mercy Hospital | David C. Pratt Cancer Center, 607 New Ballas Road, Suite 1440 | 1st Thurs. 6:30pm (call to confirm) | Kathy Bumberry, RN BSN | 314-251-6400 | kathleen.bumberry@mercy.net

MONTANA 

Bozeman | Prostate Connection Group | Cancer Support Community 102 South 11th Avenue | 4th Wed. 6pm | Amber Reilly | info@cancersupportmontana.org | 406-582-1600

NEBRASKA

Omaha | Estabrook Cancer Center | 8303 Dodge Street | 1st Thurs. 7pm | Kevin Keeley | 402-354-8350

NEVADA

Las Vegas | UsTOO | St. Rose Dominican Hospital | San Martin Campus, 8280 West Warm Spring Road | 3rd Wed. 7pm | Tony Crispino | 702-917-7779 | tcneclv@gmail.com

Reno | Mens PC Support Group | Renown Health, 3rd floor, Roseview Tower, 1155 Mill Street - Institute for Cancer Entrance | 1st + 3rd Mon. 5:30pm | Bill Riley | 775-772-5805 | billriley10@gmail.com

NEW HAMPSHIRE 

Meredith | UsTOO Living with Cancer Support Group | Meredith Community Center | 2nd + 4th Thurs. 6:30pm | J.J Santoro | 978-265-0820 | jjwinnerscircle@aol.com

NEW JERSEY 

Bedminster | Living with Advanced Stage Cancer | Cancer Support Community, 3 Crossroads Drive |  Thurs. 10:30am | 908 658 5400

Hackensack | UsTOO | Hackensack University Medical Center, John Theurer Cancer Center UMC, 92 Second Street | 3rd Wed. 10am | Joe Cavalli | 201-288-8223 | joendebcav@optonline.net 

Hasbrouck Heights | The Prostate Networking Group | Hasbrouck Heights Library, 321 Blvd | 1st Wed. 6:30pm | Joe Cavalli | 201-288-8223 | joendebcav@optonline.net

Hopewell | Cancer Support Group for Patients and Caregivers | Capital Health Medical Center | 2nd Thurs. 10am

Pennington | UsTOO Capital Health Prostate Cancer Support Group | Center for Oncology, One Capital Way | 2nd Thurs. 3pm | Karen Yatcilla | 609-394-4255 | kyatcilla@chsnj.org

Neptune | UsTOO | Midtown Community Elementary School, parking entrance, Atkins Ave & Corlies Ave, Route 33 | 3rd Thurs. 7pm | Rich Guilfoyle | 732-493-3913 | rguifoy@monmouth.edu

New Brunswick | Latinos Affected By Cancer (Latinos Afectados por Cáncer Grupo de Apoyo) | Saint Peter’s University Hospital | 2nd Sat. 10am 

Somerville | Men’s Cancer Support Group | Steeplechase Cancer Center | 2nd + 4th Wed. 6:30pm + 1st Tues. 11am

NEW MEXICO 

Albuquerque | UsTOO Prostate Cancer Support Association of NM | Bear Canyon Senior Center, 4645 Pitt Street Northeast | 1st + 3rd Sat. 12:20pm | Lou Reimer | 505-596-6842 | pchelp@pcsanm.org

NEW YORK 

Brooklyn | UsTOO | Maimonides Medical Center, 6300 8th Avenue | 1st + 3rd Tues. 9:30am | Nella Khenkin | 718-765-2655 | nkhenkin@maimonidesmed.org

Buffalo | UsTOO Buffalo Metro Chapter | VA Med Center, 3495 Bailey Avenue, 3rd Floor, Room 301 | 1st Tues 7pm | Bill Krellner | 716-836-4761 | racer3232@verizon.net

New York City | UsTOO | Weill Medical College of Cornell, 1300 York Avenue, Room A106 | 3rd Thurs. 6pm | Jack David Marcus | 917-830-4357 | info@ustoonewyork.org

Rochester | UsTOO | Jewish Community Center of Rochester, 1200 Edgewood Avenue | 2nd Thurs. 7pm | Patrick Fisher | 585-787-4011 | ustoorochesterny@gmail.com 

Rochester | Gilda's Club Prostate Cancer Support Group | 255 Alexander Street | 2nd + 4th Tues. 6 pm | info@gildasclubrochester.org | 585-423-9700

NORTH CAROLINA

Durham | Duke Cancer Patient Support Program | Duke Cancer Center | 4th Mon. 4pm | cancersupport@duke.edu | 919-684-4497

Wilmington | UsTOO | New Hanover Regional Medical Center, Classroom C | 1st Thurs. 6pm | George Gardner | 910-792-9953 | wproscasupportgp@aol.com

NORTH DAKOTA

Fargo | Cancer Support Group for Patients and Caregivers | 3000 32nd Avenue South, red conference room | 1st Tues. 1pm | April Morris | 701-364-8756

OHIO

Blue Ash | Cancer Support Community | 4918 Cooper Road | 4th Wed. 7pm, 4th Thurs. 6:30pm | 513-791-4060

Columbus | UsTOO OSU | Stephanie Spielman Comprehensive Breast Center, 1145 Olentangy River Road | 4th Wed. 7pm | Patrick DiMeo, BSN, RN | 614-293-4646 | patrick.dimeo@osumc.edu

Columbus | UsTOO "Just the Guys" | JamesCare for Life at Ohio State University | Patrick DiMeo | 614-293-4646 | patrick.dimeo@osumc.edu

Columbus | UsTOO "Just the Caregivers" | JamesCare for Life at Ohio State University | Kathie Houchens

Columbus | UsTOO Riverside Urology Group | University Plaza Hotel, 3110 Olentangy River Road | 3rd Thurs. 7pm | Herbert Riemenschneider, MD | 614-442-3000 | reimenschneider.2@osu.edu

Cincinnati | UsTOO | The Wellness Community, 4918 Cooper Road, Blue Ash | 2nd Wed. 7pm, 4th Wed. 6:30pm | Tom Young | 513-509-5040 | youngthomasa@hotmail.com 

 

OREGON

Ashland | Us TOO Rogue Valley | Ashland Community Hospital, 280 Maple Street, Conference Room 1 | 1st Tues. 7pm | Ted Clay | 541-482-6435 | tclay@ashlandhome.net

Florence | UsTOO Florence Evening Group | Presbyterian Church of the Siuslaw, 3996 Hwy 101 North | 2nd Tues. 5pm | Bob Horney | 541-997-6626 | maribob@oregonfast.net

Florence | UsTOO Florence Lunch Group | Ichiban Restaurant | 3rd Tues. 12pm | Bob Horney | 541-997-6626 | maribob@oregonfast.net

Portland | Prostate Cancer Support Group Providence Milwaukie Hospital | 10150 Southeast 32nd Avenue | 1st + 3rd Thurs. 6:30pm | Nick Kreofsky, MSW | 503-975-1034

Salem | UsTOO | Salem Hospital Ctr. for Outpatient Medicine, 875 Oak Street, Building C, 1st Floor | 3rd Tues. 7pm | Ed & Marcy Kuenzi | 503-364-9633 | eakuenzi@hotmail.com

Springfield | UsTOO We Know PCa Chapter | Oregon Urology Institute Radiation Center, 1457 G Street | 1st Wed. 5:30pm (social time & refreshments) 6pm (meeting begins) | Gina Aleshire | 541-736-2916 | gina@oregonurology.com

 

PENNSYLVANIA 

East Stroudsburg | UsTOO Pocono | Dale and Francis Hughes Cancer Center, 206 East Brown Street | 3rd Thurs. 7pm | Aalih Hussein | 570-422-1851 | ahussein@poconomedicalcenter.org

SOUTH CAROLINA 

Salem | UsTOO Golden Corner Chapter | Oconee Memorial Hospital, Board Room | 4th Fri. 3:30pm (no meeting Dec.) | Roger Dilling | 864-944-1880 | rodilling@mindspring.com

TENNESSEE

Knoxville | CSC East Tennessee | 2230 Sutherland Avenue | 2nd Sat. 10am | 865-546-4661

Memphis | UsTOO Man2Man Support Group | The West Clinic, 100 North Humphries Road | 3rd Thurs. 6pm | Clarence Williamson | 901-413-3842 | man2mangroup@att.net 

 

TEXAS

Austin | UsTOO Mike Jones Memorial Chapter | St. Davids South Medical Center, 901 West Ben White Blvd, Auditorium A, 5th Floor | 1st Tues. 7pm | Bob Wright | 956-457-9378 | rawthi@hotmail.com

Dallas | UsTOO Medical City | Building E, Classroom 2 | 3rd Thurs. 7pm (no meeting Dec.) | Carla Stuart | 972-566-5444

Georgetown | UsTOO | Scott & White Hospital Clinic, 4945 Williams Drive | 2nd Thurs. 3pm | John Fenoglio | 512-415-6801 | fenoglio38@gmail.com

Houston | Tex UsTOO | St. Luke Methodist Church, 3471 Westheimer | 2nd Mon. 7pm (No meeting, Aug.) | Peter Sterling | 713-972-0840 | pdsterlingco@aol.com

Jourdanton | Us TOO South Texas Regional Medical Center | John Staha | 830-570-7012 (call for meeting details) | johnnystaha@yahoo.com

League City | UsTOO Galveston Bay Area | UTMB Specialty Care Center, 2240 Gulf Freeway | 1st Fri. 1pm | Tom O'Neal | 281-229-5788 | tomandmarie@gmail.com 

North Park | UsTOO | Good Sheperd Medical Center | 4th Tues. 7pm | Gina Terry | 903-323-6538

San Antonio |  Us TOO Alamo Chapter | Ecum. Ctr For Religion & Health, 8310 Ewing Halsall | 1st Mon. 5:30pm | Johnny Staha | 830-570-7012 | johnnystaha@yahoo.com

UTAH

Salt Lake City | UsTOO | Sorenson Unity Center, 1388 South 809 West | 1st Wed. 6:30pm | Craig Blouin | 603-724-0532 | cblouin@comcast.net

VIRGINIA 

Fairfax | UsTOO | Inova Alexandria Hospital Cancer Center, 4320 Seminary Road | 3rd Thurs. 6pm | David McGinness | 703-504-3083 | david.mcginness@inova.org

Fairfax | UsTOO Falls Church | Life with Cancer Family Center, 8411 Pennell Street | 2nd Tues. 7:30pm (no meeting Aug. & Dec.) | Steve Haracznak | 703-281-1961 | steveh5pit@aol.com

WASHINGTON

Centralia | UsTOO Southwest Washington PCa Support Group | Providence Centralia Hospital, 914 South Scheuber Road | 4th Thurs. 7pm | Arnie Guenther | 360-388-6271 | arnieguenther@gmail.com 

Clarkston | UsTOO | Tri-State Memorial Hospital, 1221 Highland Avenue, Community Room | 1st Thurs. 12pm | Jerry Gilbert | 509-751-6930 | jgilbert1936@cableone.net 

Enumclaw | UsTOO Plateau | St. Elizabeth Hospital, 1455 Battersby Avenue | Meetings twice a month on Thurs. 6:30pm (please call for details) | Mike Gordon | 907-371-6448 | plateaupcsg@gmail.com

Friday Harbor | UsTOO | Mullis Community Senior Center, 589 Nash Street | 4th Tues. 6pm | Mike Hamlet | 360-378-5597 | mhamlette@rockisland.com

Olympia | UsTOO | Providence St. Peter Hospital, 413 Lily Road Northeast | 3rd Tues. 7pm | James Kiefert | 360-438-3644 | jimkiefert@aol.com

Shelton | UsTOO Mason County-Shelton | Olympic Bakery, 591 East Pickering Road | 2nd Tues. 10am | Bill Prastka | 360-426-2486

Shelton | UsTOO Mason County-Shelton | Mason General Hospital, 901 Mountain View Drive | 4th Mon. 7pm | Bill Prastka | 360-426-2486

Tacoma | UsTOO | University Place Presbyterian Church, 8101 27th Street West | 4th Tue. (no meeting Dec.) | Bob Freeborn | 253-566-1651 | raf0444@comcast.net  

Yakima | UsTOO Yakima Valley PC Chapter | Harman Center, 101 North 65th Avenue | 2nd Wed. 11am | Beverly Davison | 509-965-0436 | bevdav64@msn.com

WASHINGTON D.C.

D.C. | Prostate Cancer Support Group - Men Only | 2150 Pennsylvania Avenue, Northwest 20037 | 2nd Tues. 6pm | Lindsay Blair | 202-677-6291

D.C. | Caregivers Support Group - General Cancer | 2150 Pennsylvania Avenue, Northwest | 3rd Tues. 12:30pm | Lindsay Bl

WEST VIRGINIA

Huntington | Prostate Cancer Support Group | Saint Mary’s Conference Center, Breakout Room 1, 2849 Fifth Avenue | 4th Thurs. 5pm | Anissa Mondlak | 304-526-1349 

 

WISCONSIN 

Milwaukee | UsTOO | VA Medical Center, 7th Floor, GU Clinic A753 | 3rd Wed. 4pm (no meeting Jan. & Feb.) | Lisa Parent | 414-384-200 x 42114 

 

DO YOU KNOW OF A SUPPORT GROUP THAT IS NOT ON OUR LIST? LET US KNOW! 


INTERNATIONAL

Australia

Prostate Cancer Foundation of Australia | enquiries@pcfa.org.au

Canada

 Calgary | PROSTAID Calgary | Kerby Centre for the 55+ | 1133 7 Ave SW | 2nd Tues. 5pm | Kelly Fedorowich | executive.director@pccncalgary.org

Canadian Prostate Cancer Network | (866) 810-CPCN (2726) | www.cpcn.org


ONLINE SUPPORT GROUPS

 

Advanced Prostate Cancer Support Group Early Stage Prostate Cancer Support Group Gay Men and Prostate Cancer Support Group